Reports Q3 revenue $15.09M vs. $8.28M last year. “Our quarterly results reflect sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,” said Brian Webster, president and CEO. “We continue to make progress on our key operational objectives, including expansion of our commercial organization and advancement of our revenue cycle management capabilities. Following our initial public offering in March, we remain focused on delivering strong growth and executing on our commitments to patients and their prescribers.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies Ltd.: Positioned for Growth with Strong Financials and Innovative Market Strategy
- Kestra Medical Technologies: Strong Growth Potential Balanced by Current Valuation in MedTech Sector
- Kestra Medical initiated with a Buy at BofA
- Kestra Medical Technologies: Positioned for Growth in the Wearable Cardioverter Defibrillator Market
- Kestra Medical initiated with an Outperform at Wolfe Research